Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.
It has been suggested that disturbances in endocannabinoid signaling contribute to the development of depressive illness; however, at present there is insufficient evidence to allow for a full understanding of this role. To further this understanding, we performed an analysis of the endocannabinoid system in an animal model of depression. Male rats exposed to chronic, unpredictable stress (CUS) for 21 days exhibited a reduction in sexual motivation, consistent with the hypothesis that CUS in rats induces depression-like symptoms. We determined the effects of CUS, with or without concurrent treatment with the antidepressant imipramine (10 mg/kg), on CP55940 binding to the cannabinoid CB(1) receptor; whole tissue endocannabinoid content; and fatty acid amide hydrolase (FAAH) activity in the prefrontal cortex, hippocampus, hypothalamus, amygdala, midbrain and ventral striatum. Exposure to CUS resulted in a significant increase in CB(1) receptor binding site density in the prefrontal cortex and a decrease in CB(1) receptor binding site density in the hippocampus, hypothalamus and ventral striatum. Except in the hippocampus, these CUS-induced alterations in CB(1) receptor binding site density were attenuated by concurrent antidepressant treatment. CUS alone produced a significant reduction in N-arachidonylethanolamine (anandamide) content in every brain region examined, which was not reversed by antidepressant treatment. These data suggest that the endocannabinoid system in cortical and subcortical structures is differentially altered in an animal model of depression and that the effects of CUS on CB(1) receptor binding site density are attenuated by antidepressant treatment while those on endocannabinoid content are not.
Hill
Matthew N
MN
Department of Psychology, University of British Columbia, Vancouver, British Columbia, Canada.
Carrier
Erica J
EJ
McLaughlin
Ryan J
RJ
Morrish
Anna C
AC
Meier
Sarah E
SE
Hillard
Cecilia J
CJ
Gorzalka
Boris B
BB
D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D001095:Arachidonic Acids / Q000378:metabolism; D001921:Brain / Q000378:metabolism* / Q000503:physiopathology; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D003511:Cyclohexanols / Q000494:pharmacology; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000378:metabolism* / Q000503:physiopathology; D004195:Disease Models, Animal; D063388:Endocannabinoids; D007099:Imipramine / Q000494:pharmacology; D008297:Male; D009042:Motivation; D053284:Polyunsaturated Alkamides / Q000378:metabolism; D051381:Rats; D020318:Rats, Long-Evans; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects / Q000378:metabolism; D012726:Sexual Behavior, Animal / Q000187:drug effects / Q000502:physiology; D013315:Stress, Psychological / Q000378:metabolism / Q000503:physiopathology
D000700:Analgesics; D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D003511:Cyclohexanols; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D043884:Receptor, Cannabinoid, CB1; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; D007099:Imipramine; C078814:anandamide